• Net cash from operating activities of $858k
• Quarterly receipts from customers were $388k
• R&D tax incentive of $678k received for FY24

BOD Science Limited (Subject to a Deed of Company Arrangement) (ASX: BOD) has provided an update on its activities for the three-month period ended 30 June 2025 (Q4 FY2025). The company reported a net cash inflow from operating activities of $858k, an increase of $816k compared to Q3 FY2025. This increase was driven by the receipt of the FY24 R&D tax incentive of $678k and a contribution from Biortica of $255k. Quarterly receipts from customers were $388k, an increase of 5% from the previous quarter and a 326% increase from the prior corresponding period, due to increased sales volumes driven by the introduction of new SKUs. The company made payments totalling $35k to related parties during the quarter, representing remuneration paid to a director. The company has entered into a binding Share Purchase Agreement with the ordinary shareholders of Biortica, which is subject to conditions subsequent being met, together with the effectuation of the Deed of Company Arrangement (DOCA) and the company satisfying the re-compliance requirements with the ASX Listing Rules, including all necessary shareholder approvals. It is expected that a notice of meeting will be sent to the company's shareholders soon after Biortica complies with the conditions subsequent, informing them that an extraordinary general meeting has been scheduled at which the shareholders will vote upon whether to approve the various resolutions as detailed in Biortica's DOCA proposal.

The company has entered into a binding Share Purchase Agreement with the ordinary shareholders of Biortica, which is subject to conditions subsequent being met, together with the effectuation of the Deed of Company Arrangement (DOCA) and the company satisfying the re-compliance requirements with the ASX Listing Rules, including all necessary shareholder approvals. It is expected that a notice of meeting will be sent to the company's shareholders soon after Biortica complies with the conditions subsequent, informing them that an extraordinary general meeting has been scheduled at which the shareholders will vote upon whether to approve the various resolutions as detailed in Biortica's DOCA proposal.